Prima BioMed Ltd. (Nasdaq: PBMD) reported upbeat interim data for its TACTI-mel clinical program for IMP321 in unresectable or metastatic melanoma patients lifting the stock price 17 cents to close at $2.50.
Prima Biomed reports upbeat interim data
December 29, 2016 at 16:17 PM EST